Winslow Capital Management LLC Cuts Stock Position in Boston Scientific Co. (NYSE:BSX)

Winslow Capital Management LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 8.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,134,072 shares of the medical equipment provider's stock after selling 286,624 shares during the period. Winslow Capital Management LLC owned about 0.21% of Boston Scientific worth $279,935,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. TFC Financial Management Inc. increased its holdings in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares during the last quarter. Global Wealth Strategies & Associates lifted its position in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC bought a new stake in Boston Scientific in the 4th quarter valued at $29,000. Valley National Advisers Inc. raised its holdings in shares of Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC bought a new stake in Boston Scientific during the 4th quarter worth about $36,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. Truist Financial decreased their price target on shares of Boston Scientific from $120.00 to $113.00 and set a "buy" rating for the company in a research note on Friday. Piper Sandler boosted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a report on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $109.04.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.27 during trading on Monday, hitting $93.94. The company had a trading volume of 2,148,311 shares, compared to its average volume of 6,341,201. The firm has a market capitalization of $138.94 billion, a P/E ratio of 75.15, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock's 50-day moving average price is $100.54 and its 200 day moving average price is $94.10. Boston Scientific Co. has a one year low of $66.80 and a one year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock valued at $13,948,476 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.